Canada-based clinical-stage biotechnology company Thryv Therapeutics Inc on Wednesday reported encouraging results from a recently completed Phase 1 clinical study evaluating THRV-1268 in obese participants.

The study was conducted in a dedicated cohort of obese participants (BMI > 30 kg/m2). Participants demonstrated absolute and placebo-corrected QTcF shortening from baseline after a single dose of THRV-1268. The dataset supports the compound's differentiated electrophysiologic profile under conditions relevant to cardiometabolic disease, including increased body weight and body mass index.

The study assessed pharmacodynamics, pharmacokinetics, safety, and tolerability of THRV-1268 across two single ascending doses in obese participants. It appeared to be well tolerated with no serious adverse events reported.

A comparative bioavailability evaluation of a new tablet formulation of THRV-1268 showed equivalent pharmacokinetic profiles between the tablet and oral suspension. Based on data from this study, weight-based dose adjustments are not planned for the upcoming Phase 2a ASPIRE clinical trial in heart failure.